Hologic Key Executives
This section highlights Hologic's key executives, including their titles and compensation details.
Find Contacts at Hologic
(Showing 0 of )
Hologic Earnings
This section highlights Hologic's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2025 | 2025-02-05 | $1.02 | $1.03 |
| Read Transcript | Q4 | 2024 | 2024-11-04 | $1.01 | $1.01 |
| Read Transcript | Q3 | 2024 | 2024-07-29 | $1.02 | $1.06 |
| Read Transcript | Q2 | 2024 | 2024-05-02 | $0.98 | $1.03 |
| Read Transcript | Q1 | 2024 | 2024-02-01 | $0.95 | $0.98 |
| Read Transcript | Q4 | 2023 | 2023-11-09 | $0.85 | $0.89 |
| Read Transcript | Q3 | 2023 | 2023-07-31 | $0.88 | $0.93 |
| Read Transcript | Q2 | 2023 | 2023-05-01 | $0.88 | $1.06 |
| Read Transcript | Q1 | 2023 | 2023-02-01 | $0.90 | $1.07 |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
$61.32
Stock Price
$13.76B
Market Cap
-
Employees
Marlborough, MA
Location
Financial Statements
Access annual & quarterly financial statements for Hologic, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | September 28, 2024 | September 30, 2023 | September 24, 2022 | September 25, 2021 | September 26, 2020 |
|---|---|---|---|---|---|
| Revenue | $4.03B | $4.03B | $4.86B | $5.63B | $3.78B |
| Cost of Revenue | $1.80B | $1.96B | $1.87B | $1.84B | $1.55B |
| Gross Profit | $2.23B | $2.07B | $3.00B | $3.80B | $2.23B |
| Gross Profit Ratio | 55.28% | 51.40% | 61.64% | 67.40% | 58.98% |
| Research and Development Expenses | $272.80M | $294.30M | $283.40M | $276.30M | $222.50M |
| General and Administrative Expenses | $409.40M | $392.40M | $407.70M | $433.20M | $356.00M |
| Selling and Marketing Expenses | $585.40M | $595.20M | $630.30M | $561.20M | $484.60M |
| Selling General and Administrative Expenses | $994.80M | $987.60M | $1.04B | $994.40M | $840.60M |
| Other Expenses | $77.60M | $-1.70M | $45.20M | $42.20M | $39.70M |
| Operating Expenses | $1.35B | $1.31B | $1.37B | $1.31B | $1.10B |
| Cost and Expenses | $3.06B | $3.27B | $3.23B | $3.15B | $2.65B |
| Interest Income | $108.70M | $120.50M | $12.90M | $1.40M | $4.30M |
| Interest Expense | $122.10M | $111.10M | $95.10M | $93.60M | $116.50M |
| Depreciation and Amortization | $309.00M | $323.40M | $430.10M | $406.90M | $376.00M |
| EBITDA | $1.30B | $1.11B | $2.11B | $2.86B | $1.50B |
| EBITDA Ratio | 32.16% | 29.87% | 43.28% | 51.24% | 40.09% |
| Operating Income | $970.20M | $668.40M | $1.64B | $2.48B | $1.10B |
| Operating Income Ratio | 24.07% | 16.58% | 33.73% | 44.04% | 29.26% |
| Total Other Income Expenses Net | $-105.10M | $7.70M | $-52.00M | $-119.20M | $-103.10M |
| Income Before Tax | $865.10M | $676.10M | $1.59B | $2.36B | $1.00B |
| Income Before Tax Ratio | 21.46% | 16.78% | 32.66% | 41.92% | 26.53% |
| Income Tax Expense | $75.60M | $220.10M | $286.20M | $491.40M | $-108.60M |
| Net Income | $789.50M | $456.00M | $1.30B | $1.87B | $1.12B |
| Net Income Ratio | 19.59% | 11.31% | 26.77% | 33.23% | 29.53% |
| EPS | $3.35 | $1.85 | $5.18 | $7.28 | $4.24 |
| EPS Diluted | $3.32 | $1.83 | $5.13 | $7.21 | $4.21 |
| Weighted Average Shares Outstanding | 235.72M | 246.77M | 251.53M | 257.05M | 262.73M |
| Weighted Average Shares Outstanding Diluted | 237.55M | 248.83M | 253.84M | 259.71M | 264.61M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 28, 2024 | September 28, 2024 | June 29, 2024 | March 30, 2024 | December 30, 2023 | September 30, 2023 | July 01, 2023 | April 01, 2023 | December 31, 2022 | September 24, 2022 | June 25, 2022 | March 26, 2022 | December 25, 2021 | September 25, 2021 | June 26, 2021 | March 27, 2021 | December 26, 2020 | September 26, 2020 | June 27, 2020 | March 28, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.02B | $987.90M | $1.01B | $1.02B | $1.01B | $945.30M | $984.40M | $1.03B | $1.07B | $953.20M | $1.00B | $1.44B | $1.47B | $1.32B | $1.17B | $1.54B | $1.61B | $1.35B | $822.90M | $756.10M |
| Cost of Revenue | $441.30M | $430.30M | $443.10M | $455.30M | $445.60M | $445.00M | $616.90M | $440.70M | $456.30M | $438.50M | $452.90M | $489.10M | $484.80M | $488.50M | $466.70M | $451.80M | $429.40M | $415.20M | $356.80M | $360.30M |
| Gross Profit | $580.50M | $557.60M | $568.30M | $562.50M | $567.50M | $500.30M | $367.50M | $585.80M | $617.90M | $514.70M | $549.80M | $946.60M | $986.30M | $828.10M | $701.60M | $1.09B | $1.18B | $931.80M | $466.10M | $395.80M |
| Gross Profit Ratio | 56.81% | 56.40% | 56.20% | 55.30% | 56.00% | 52.90% | 37.30% | 57.10% | 57.50% | 54.00% | 54.80% | 65.90% | 67.00% | 62.90% | 60.10% | 70.60% | 73.30% | 69.18% | 56.64% | 52.35% |
| Research and Development Expenses | $60.30M | $67.30M | $64.10M | $74.60M | $66.80M | $72.90M | $72.60M | $74.00M | $74.80M | $76.00M | $65.10M | $69.50M | $72.80M | $76.50M | $69.00M | $71.50M | $59.30M | $57.00M | $55.10M | $49.30M |
| General and Administrative Expenses | $115.70M | $103.20M | $94.00M | $100.40M | $111.80M | $92.90M | $90.20M | $100.80M | $108.50M | $97.20M | $91.90M | $100.50M | $117.90M | $135.40M | $117.30M | $88.90M | $91.50M | $95.60M | $105.30M | $66.50M |
| Selling and Marketing Expenses | $166.10M | $146.00M | $146.30M | $144.20M | $148.90M | $139.50M | $149.80M | $142.40M | $163.50M | $159.30M | $152.30M | $171.40M | $147.40M | $159.10M | $142.70M | $131.50M | $128.00M | $125.70M | $103.50M | $110.60M |
| Selling General and Administrative Expenses | $281.80M | $249.20M | $240.30M | $244.60M | $260.70M | $232.40M | $240.00M | $243.20M | $272.00M | $256.50M | $244.20M | $271.90M | $265.30M | $294.50M | $260.00M | $220.40M | $219.50M | $221.30M | $208.80M | $177.10M |
| Other Expenses | $8.60M | $11.10M | $200.00K | $9.40M | $-8.80M | $5.30M | $5.90M | $2.90M | $-15.80M | $17.30M | $4.80M | $11.30M | $6.50M | $-6.40M | $100.00K | $4.70M | $10.10M | $9.00M | $4.30M | $-7.50M |
| Operating Expenses | $350.70M | $327.60M | $304.40M | $319.20M | $340.80M | $311.50M | $319.70M | $324.30M | $354.40M | $344.50M | $320.50M | $352.70M | $348.90M | $382.50M | $339.40M | $302.10M | $288.90M | $288.50M | $274.10M | $236.50M |
| Cost and Expenses | $792.00M | $757.80M | $747.50M | $774.50M | $786.40M | $756.50M | $936.60M | $765.00M | $810.70M | $783.00M | $773.40M | $841.80M | $833.70M | $871.00M | $806.10M | $753.90M | $718.30M | $703.70M | $630.90M | $596.80M |
| Interest Income | $24.20M | $28.40M | $28.40M | $24.00M | $27.90M | $35.90M | $32.50M | $31.50M | $20.60M | $9.30M | $2.40M | $800.00K | $500.00K | $200.00K | $400.00K | $300.00K | $400.00K | $300.00K | $500.00K | $1.30M |
| Interest Expense | $30.50M | $31.90M | $31.90M | $32.30M | $26.00M | $28.10M | $27.70M | $27.20M | $28.10M | $24.10M | $22.70M | $22.60M | $25.70M | $22.70M | $21.60M | $21.30M | $28.10M | $25.00M | $27.40M | $31.30M |
| Depreciation and Amortization | $74.00M | $74.60M | $72.30M | $73.70M | $88.40M | $75.50M | $81.10M | $80.80M | $85.90M | $106.60M | $109.40M | $106.20M | $108.00M | $117.80M | $101.20M | $95.20M | $92.80M | $94.30M | $93.60M | $93.70M |
| EBITDA | $352.00M | $328.10M | $344.90M | $317.50M | $305.70M | $249.20M | $120.90M | $387.30M | $353.10M | $274.10M | $380.50M | $703.20M | $755.60M | $551.10M | $460.30M | $883.90M | $953.30M | $736.70M | $286.30M | $243.90M |
| EBITDA Ratio | 34.45% | 33.21% | 33.24% | 31.15% | 19.56% | 32.32% | 17.01% | 36.70% | 32.97% | 31.83% | 34.50% | 48.96% | 51.15% | 34.25% | 39.70% | 57.49% | 61.16% | 49.21% | 35.29% | 32.64% |
| Operating Income | $229.80M | $230.10M | $263.90M | $243.30M | $198.20M | $132.50M | $1.40M | $272.10M | $262.40M | $140.90M | $263.90M | $594.10M | $641.30M | $439.50M | $358.60M | $796.80M | $885.50M | $632.80M | $191.00M | $156.40M |
| Operating Income Ratio | 22.49% | 23.29% | 26.09% | 23.90% | 19.56% | 14.02% | 0.14% | 26.51% | 24.43% | 14.78% | 26.32% | 41.38% | 43.59% | 33.38% | 30.69% | 51.82% | 55.01% | 46.98% | 23.21% | 20.69% |
| Total Other Income Expenses Net | $17.70M | $-8.50M | $-23.20M | $-31.80M | $-6.90M | $13.10M | $10.70M | $7.20M | $-23.30M | $-35.00M | $-15.50M | $-19.70M | $-19.40M | $-28.90M | $-21.10M | $-16.30M | $-53.10M | $-15.70M | $-22.60M | $-37.50M |
| Income Before Tax | $247.50M | $221.60M | $240.70M | $211.50M | $191.30M | $145.60M | $12.10M | $279.30M | $239.10M | $143.40M | $248.40M | $574.40M | $621.90M | $410.60M | $337.50M | $780.50M | $832.40M | $617.10M | $168.40M | $118.90M |
| Income Before Tax Ratio | 24.22% | 22.43% | 23.80% | 20.78% | 18.88% | 15.40% | 1.23% | 27.21% | 22.26% | 15.04% | 24.77% | 40.01% | 42.27% | 31.19% | 28.89% | 50.76% | 51.71% | 45.81% | 20.46% | 15.73% |
| Income Tax Expense | $46.50M | $43.00M | $46.20M | $41.60M | $-55.20M | $55.00M | $52.60M | $60.80M | $51.70M | $24.70M | $20.00M | $118.70M | $122.70M | $81.80M | $69.40M | $161.10M | $179.00M | $123.50M | $32.00M | $24.10M |
| Net Income | $201.00M | $178.60M | $194.50M | $169.90M | $246.50M | $90.60M | $-40.50M | $218.50M | $187.40M | $118.70M | $228.40M | $455.70M | $499.20M | $328.80M | $268.40M | $619.90M | $654.40M | $494.90M | $137.90M | $96.30M |
| Net Income Ratio | 19.67% | 18.08% | 19.23% | 16.69% | 24.33% | 9.58% | -4.11% | 21.29% | 17.45% | 12.45% | 22.78% | 31.74% | 33.93% | 24.97% | 22.97% | 40.32% | 40.65% | 36.74% | 16.76% | 12.74% |
| EPS | $0.87 | $0.76 | $0.83 | $0.72 | $1.03 | $0.37 | $-0.16 | $0.88 | $0.76 | $0.47 | $0.91 | $1.81 | $1.97 | $1.29 | $1.05 | $2.40 | $2.53 | $1.90 | $0.53 | $0.37 |
| EPS Diluted | $0.87 | $0.76 | $0.82 | $0.72 | $1.03 | $0.37 | $-0.16 | $0.87 | $0.75 | $0.47 | $0.90 | $1.80 | $1.95 | $1.28 | $1.04 | $2.38 | $2.50 | $1.88 | $0.53 | $0.36 |
| Weighted Average Shares Outstanding | 230.28M | 233.77M | 234.60M | 235.89M | 238.63M | 245.13M | 246.91M | 247.73M | 247.32M | 250.28M | 250.76M | 251.57M | 253.50M | 254.88M | 256.23M | 258.47M | 258.61M | 259.91M | 259.87M | 263.24M |
| Weighted Average Shares Outstanding Diluted | 232.11M | 235.97M | 236.47M | 237.56M | 240.21M | 247.14M | 246.91M | 249.79M | 249.28M | 252.56M | 253.09M | 253.66M | 256.07M | 257.71M | 258.58M | 260.75M | 261.79M | 263.18M | 261.05M | 264.51M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | September 28, 2024 | September 30, 2023 | September 24, 2022 | September 25, 2021 | September 26, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.16B | $2.72B | $2.34B | $1.17B | $701.00M |
| Short Term Investments | $173.40M | $16.20M | $31.90M | $- | $- |
| Cash and Short Term Investments | $2.33B | $2.72B | $2.34B | $1.17B | $701.00M |
| Net Receivables | $600.40M | $625.60M | $617.60M | $942.70M | $1.03B |
| Inventory | $679.80M | $617.60M | $623.70M | $501.20M | $395.10M |
| Other Current Assets | $209.50M | $218.80M | $281.20M | $554.50M | $136.10M |
| Total Current Assets | $3.82B | $4.18B | $3.86B | $3.17B | $2.22B |
| Property Plant Equipment Net | $537.80M | $517.00M | $481.60M | $564.70M | $491.50M |
| Goodwill | $3.44B | $3.28B | $3.24B | $3.28B | $2.66B |
| Intangible Assets | $844.60M | $888.60M | $1.28B | $1.66B | $1.31B |
| Goodwill and Intangible Assets | $4.29B | $4.17B | $4.52B | $4.94B | $3.97B |
| Long Term Investments | $96.40M | $-20.20M | $5.50M | $9.50M | $11.40M |
| Tax Assets | $- | $20.20M | $16.20M | $21.90M | $15.50M |
| Other Non-Current Assets | $410.80M | $267.90M | $188.80M | $214.30M | $489.70M |
| Total Non-Current Assets | $5.33B | $4.95B | $5.21B | $5.75B | $4.97B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $9.16B | $9.14B | $9.07B | $8.92B | $7.20B |
| Account Payables | $203.80M | $175.20M | $197.70M | $215.90M | $178.80M |
| Short Term Debt | $64.80M | $310.50M | $41.40M | $343.50M | $350.30M |
| Tax Payables | $69.40M | $31.60M | $44.20M | $70.90M | $125.30M |
| Deferred Revenue | $212.90M | $199.20M | $186.50M | $198.00M | $186.10M |
| Other Current Liabilities | $486.30M | $490.80M | $467.90M | $498.50M | $398.80M |
| Total Current Liabilities | $1.04B | $1.21B | $937.70M | $1.33B | $1.24B |
| Long Term Debt | $2.59B | $2.59B | $2.88B | $2.80B | $2.80B |
| Deferred Revenue Non-Current | $13.80M | $13.80M | $9.40M | $20.30M | $12.90M |
| Deferred Tax Liabilities Non-Current | $371.20M | $20.20M | $90.80M | $250.50M | $201.80M |
| Other Non-Current Liabilities | $10.60M | $13.20M | $276.90M | $302.60M | $237.60M |
| Total Non-Current Liabilities | $2.99B | $2.92B | $3.26B | $3.37B | $3.25B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $4.03B | $4.12B | $4.20B | $4.70B | $4.49B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $- | $3.00M | $3.00M | $3.00M | $2.90M |
| Retained Earnings | $- | $2.06B | $1.60B | $298.30M | $-1.57B |
| Accumulated Other Comprehensive Income Loss | $-111.50M | $-147.60M | $-238.20M | $-59.10M | $-49.70M |
| Other Total Stockholders Equity | $5.24B | $3.11B | $3.51B | $3.98B | $4.33B |
| Total Stockholders Equity | $5.13B | $5.02B | $4.88B | $4.22B | $2.71B |
| Total Equity | $5.13B | $5.02B | $4.88B | $4.22B | $2.71B |
| Total Liabilities and Stockholders Equity | $9.16B | $9.14B | $9.07B | $8.92B | $7.20B |
| Minority Interest | $- | $- | $- | $- | $2.10M |
| Total Liabilities and Total Equity | $9.16B | $9.14B | $9.07B | $8.92B | $7.20B |
| Total Investments | $269.80M | $-20.20M | $5.50M | $9.50M | $11.40M |
| Total Debt | $2.66B | $2.82B | $2.82B | $3.03B | $3.04B |
| Net Debt | $497.80M | $95.70M | $483.90M | $1.85B | $2.34B |
Balance Sheet Charts
| Breakdown | December 28, 2024 | September 28, 2024 | June 29, 2024 | March 30, 2024 | December 30, 2023 | September 30, 2023 | July 01, 2023 | April 01, 2023 | December 31, 2022 | September 24, 2022 | June 25, 2022 | March 26, 2022 | December 25, 2021 | September 25, 2021 | June 26, 2021 | March 27, 2021 | December 26, 2020 | September 26, 2020 | June 27, 2020 | March 28, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.78B | $2.16B | $2.44B | $2.18B | $1.93B | $2.72B | $2.77B | $2.58B | $2.44B | $2.34B | $2.38B | $2.29B | $1.42B | $1.17B | $827.60M | $816.40M | $868.70M | $701.00M | $744.20M | $799.80M |
| Short Term Investments | $190.60M | $173.40M | $8.50M | $7.90M | $22.00M | $16.20M | $24.00M | $27.10M | $35.10M | $- | $19.00M | $5.50M | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.97B | $2.33B | $2.44B | $2.18B | $1.93B | $2.72B | $2.77B | $2.58B | $2.44B | $2.34B | $2.38B | $2.29B | $1.42B | $1.17B | $827.60M | $816.40M | $868.70M | $701.00M | $744.20M | $799.80M |
| Net Receivables | $631.40M | $600.40M | $628.50M | $647.10M | $670.90M | $625.60M | $686.80M | $714.00M | $673.80M | $617.60M | $702.90M | $813.00M | $975.60M | $942.70M | $943.20M | $1.21B | $1.22B | $1.03B | $728.00M | $597.20M |
| Inventory | $707.10M | $679.80M | $665.50M | $649.20M | $633.60M | $617.60M | $680.10M | $687.60M | $677.70M | $623.70M | $581.20M | $526.10M | $518.30M | $501.20M | $502.90M | $456.20M | $420.20M | $395.10M | $413.60M | $401.30M |
| Other Current Assets | $182.40M | $209.50M | $369.40M | $312.40M | $257.60M | $218.80M | $241.10M | $227.60M | $228.40M | $281.20M | $249.60M | $251.50M | $591.50M | $554.50M | $144.50M | $177.50M | $91.30M | $136.10M | $97.00M | $138.30M |
| Total Current Assets | $3.49B | $3.82B | $4.00B | $3.79B | $3.49B | $4.18B | $4.34B | $4.21B | $4.02B | $3.86B | $3.91B | $3.88B | $3.51B | $3.17B | $2.42B | $2.66B | $2.60B | $2.22B | $1.98B | $1.94B |
| Property Plant Equipment Net | $537.20M | $537.80M | $528.80M | $524.80M | $527.00M | $517.00M | $493.30M | $497.90M | $494.30M | $550.50M | $490.10M | $506.90M | $554.30M | $564.70M | $551.10M | $533.60M | $514.50M | $491.50M | $456.20M | $445.30M |
| Goodwill | $3.42B | $3.44B | $3.29B | $3.29B | $3.31B | $3.28B | $3.30B | $3.30B | $3.29B | $3.24B | $3.29B | $3.32B | $3.33B | $3.28B | $3.26B | $2.86B | $2.66B | $2.66B | $2.59B | $2.59B |
| Intangible Assets | $793.30M | $844.60M | $687.60M | $751.90M | $832.70M | $888.60M | $940.10M | $1.20B | $1.26B | $1.28B | $1.44B | $1.55B | $1.65B | $1.66B | $1.80B | $1.45B | $1.24B | $1.31B | $1.25B | $1.33B |
| Goodwill and Intangible Assets | $4.22B | $4.29B | $3.98B | $4.04B | $4.14B | $4.17B | $4.24B | $4.50B | $4.54B | $4.52B | $4.72B | $4.87B | $4.98B | $4.94B | $5.07B | $4.30B | $3.91B | $3.97B | $3.85B | $3.92B |
| Long Term Investments | $47.90M | $96.40M | $6.20M | $6.30M | $-19.80M | $-20.20M | $-19.40M | $100.00K | $- | $12.50M | $9.60M | $12.20M | $-242.90M | $9.50M | $-284.80M | $-229.80M | $-189.40M | $11.40M | $-214.10M | $-235.90M |
| Tax Assets | $- | $59.40M | $17.80M | $18.40M | $19.80M | $20.20M | $19.40M | $33.40M | $71.70M | $16.20M | $208.30M | $-12.20M | $242.90M | $21.90M | $284.80M | $229.80M | $189.40M | $15.50M | $214.10M | $235.90M |
| Other Non-Current Assets | $433.80M | $351.40M | $361.60M | $331.90M | $309.70M | $267.90M | $267.00M | $206.80M | $158.10M | $112.90M | $18.00M | $257.00M | $244.70M | $214.30M | $556.30M | $543.20M | $531.80M | $489.70M | $518.70M | $519.10M |
| Total Non-Current Assets | $5.24B | $5.33B | $4.89B | $4.93B | $4.98B | $4.95B | $5.00B | $5.24B | $5.27B | $5.21B | $5.45B | $5.63B | $5.78B | $5.75B | $6.17B | $5.38B | $4.95B | $4.97B | $4.82B | $4.89B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $8.73B | $9.16B | $8.89B | $8.71B | $8.47B | $9.14B | $9.34B | $9.45B | $9.29B | $9.07B | $9.36B | $9.51B | $9.29B | $8.92B | $8.59B | $8.04B | $7.55B | $7.20B | $6.80B | $6.82B |
| Account Payables | $236.70M | $203.80M | $202.00M | $202.50M | $183.80M | $175.20M | $180.60M | $187.40M | $201.80M | $197.70M | $216.60M | $224.80M | $202.20M | $215.90M | $208.40M | $225.10M | $184.30M | $178.80M | $127.30M | $134.40M |
| Short Term Debt | $53.40M | $64.80M | $43.90M | $43.80M | $43.80M | $310.50M | $34.70M | $29.10M | $23.80M | $41.40M | $14.50M | $263.20M | $255.30M | $343.50M | $466.80M | $80.90M | $78.90M | $350.30M | $567.30M | $807.90M |
| Tax Payables | $- | $69.40M | $105.50M | $146.90M | $101.80M | $62.30M | $33.70M | $40.60M | $31.10M | $44.20M | $36.30M | $- | $30.30M | $70.90M | $63.00M | $85.40M | $29.90M | $125.30M | $45.50M | $62.60M |
| Deferred Revenue | $187.50M | $212.90M | $219.00M | $208.00M | $190.60M | $199.20M | $232.90M | $230.50M | $191.60M | $186.50M | $199.60M | $205.00M | $192.10M | $198.00M | $213.10M | $198.50M | $182.90M | $186.10M | $175.10M | $172.60M |
| Other Current Liabilities | $524.80M | $486.30M | $428.80M | $350.20M | $375.80M | $460.10M | $499.40M | $467.40M | $507.90M | $467.90M | $530.40M | $608.60M | $595.50M | $498.50M | $510.20M | $443.50M | $578.00M | $398.80M | $430.50M | $303.40M |
| Total Current Liabilities | $1.00B | $1.04B | $1.00B | $954.60M | $899.00M | $1.21B | $981.30M | $955.00M | $956.20M | $937.70M | $1.00B | $1.31B | $1.28B | $1.33B | $1.46B | $1.04B | $1.06B | $1.24B | $1.35B | $1.48B |
| Long Term Debt | $22.20M | $2.59B | $2.52B | $2.53B | $2.54B | $2.59B | $2.81B | $2.81B | $2.82B | $2.88B | $2.85B | $2.85B | $2.84B | $2.80B | $2.68B | $2.70B | $2.71B | $2.80B | $2.82B | $2.84B |
| Deferred Revenue Non-Current | $12.40M | $13.80M | $14.80M | $14.80M | $14.20M | $13.80M | $13.70M | $12.80M | $10.90M | $9.40M | $10.90M | $18.10M | $20.20M | $20.30M | $15.00M | $13.40M | $12.50M | $12.90M | $12.60M | $15.00M |
| Deferred Tax Liabilities Non-Current | $53.70M | $371.20M | $17.80M | $18.40M | $19.80M | $20.20M | $19.40M | $33.40M | $71.70M | $90.80M | $208.30M | $232.10M | $242.90M | $250.50M | $284.80M | $229.80M | $189.40M | $201.80M | $214.10M | $235.90M |
| Other Non-Current Liabilities | $2.86B | $10.60M | $385.70M | $354.30M | $345.30M | $13.20M | $336.00M | $332.00M | $335.10M | $276.90M | $287.00M | $313.10M | $383.30M | $302.60M | $271.50M | $273.70M | $317.50M | $237.60M | $154.60M | $162.40M |
| Total Non-Current Liabilities | $2.95B | $2.99B | $2.94B | $2.92B | $2.92B | $2.92B | $3.17B | $3.19B | $3.24B | $3.26B | $3.36B | $3.42B | $3.49B | $3.37B | $3.25B | $3.21B | $3.23B | $3.25B | $3.20B | $3.25B |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $3.96B | $4.03B | $3.94B | $3.87B | $3.82B | $4.12B | $4.16B | $4.15B | $4.20B | $4.20B | $4.36B | $4.72B | $4.77B | $4.70B | $4.71B | $4.25B | $4.28B | $4.49B | $4.54B | $4.73B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $- | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $3.00M | $2.90M | $2.90M | $2.90M |
| Retained Earnings | $- | $- | $2.67B | $2.47B | $2.30B | $2.06B | $1.97B | $2.01B | $1.79B | $1.60B | $1.48B | $1.25B | $797.50M | $298.30M | $-30.50M | $-298.90M | $-918.80M | $-1.57B | $-2.07B | $-2.21B |
| Accumulated Other Comprehensive Income Loss | $-162.70M | $-111.50M | $-139.50M | $-137.00M | $-118.80M | $-147.60M | $-113.60M | $-118.40M | $-127.30M | $-238.20M | $-147.70M | $-104.10M | $-89.00M | $-59.10M | $-42.20M | $-35.80M | $-30.70M | $-49.70M | $-61.90M | $-58.90M |
| Other Total Stockholders Equity | $4.94B | $5.24B | $2.42B | $2.51B | $2.47B | $3.11B | $3.33B | $3.41B | $3.43B | $3.51B | $3.66B | $3.64B | $3.81B | $3.98B | $3.95B | $4.13B | $4.21B | $4.33B | $4.38B | $4.35B |
| Total Stockholders Equity | $4.77B | $5.13B | $4.95B | $4.84B | $4.65B | $5.02B | $5.18B | $5.30B | $5.09B | $4.88B | $5.00B | $4.79B | $4.52B | $4.22B | $3.88B | $3.79B | $3.27B | $2.71B | $2.26B | $2.09B |
| Total Equity | $4.77B | $5.13B | $4.95B | $4.84B | $4.65B | $5.02B | $5.18B | $5.30B | $5.09B | $4.88B | $5.00B | $4.79B | $4.52B | $4.22B | $3.88B | $3.79B | $3.27B | $2.71B | $2.26B | $2.09B |
| Total Liabilities and Stockholders Equity | $8.73B | $9.16B | $8.89B | $8.71B | $8.47B | $9.14B | $9.34B | $9.45B | $9.29B | $9.07B | $9.36B | $9.51B | $9.29B | $8.92B | $8.59B | $8.04B | $7.55B | $7.20B | $6.80B | $6.82B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $600.00K | $1.10M | $2.10M | $3.50M | $5.10M |
| Total Liabilities and Total Equity | $8.73B | $9.16B | $8.89B | $8.71B | $8.47B | $9.14B | $9.34B | $9.45B | $9.29B | $9.07B | $9.36B | $9.51B | $9.29B | $8.92B | $8.59B | $8.04B | $7.55B | $7.20B | $6.80B | $6.82B |
| Total Investments | $238.50M | $269.80M | $6.20M | $6.30M | $2.20M | $-20.20M | $-19.40M | $100.00K | $35.10M | $12.50M | $28.60M | $17.70M | $-242.90M | $9.50M | $-284.80M | $-229.80M | $-189.40M | $11.40M | $-214.10M | $-235.90M |
| Total Debt | $46.80M | $2.53B | $2.56B | $2.57B | $2.58B | $2.82B | $2.82B | $2.82B | $2.83B | $2.92B | $2.84B | $3.09B | $3.09B | $3.03B | $3.14B | $2.77B | $2.78B | $3.04B | $3.32B | $3.58B |
| Net Debt | $-1.74B | $374.40M | $120.10M | $388.50M | $645.90M | $95.70M | $56.10M | $241.70M | $385.50M | $582.10M | $469.20M | $802.30M | $1.67B | $1.85B | $2.31B | $1.96B | $1.91B | $2.34B | $2.57B | $2.78B |
Annual Cash Flow
| Breakdown | September 28, 2024 | September 30, 2023 | September 24, 2022 | September 25, 2021 | September 26, 2020 |
|---|---|---|---|---|---|
| Net Income | $789.50M | $456.00M | $1.30B | $1.87B | $1.11B |
| Depreciation and Amortization | $309.00M | $323.40M | $430.10M | $406.90M | $376.00M |
| Deferred Income Tax | $-72.10M | $-109.10M | $-166.20M | $-70.10M | $-94.40M |
| Stock Based Compensation | $82.30M | $79.60M | $66.70M | $65.00M | $83.30M |
| Change in Working Capital | $84.10M | $11.80M | $454.20M | $13.00M | $-636.30M |
| Accounts Receivables | $41.00M | $-1.50M | $272.30M | $110.90M | $-427.10M |
| Inventory | $-47.40M | $-4.90M | $-136.60M | $-84.10M | $-25.30M |
| Accounts Payables | $22.20M | $-23.00M | $-14.40M | $20.40M | $-4.90M |
| Other Working Capital | $68.30M | $41.20M | $332.90M | $-34.20M | $-179.00M |
| Other Non Cash Items | $92.40M | $289.50M | $38.90M | $45.90M | $57.50M |
| Net Cash Provided by Operating Activities | $1.29B | $1.05B | $2.13B | $2.33B | $896.60M |
| Investments in Property Plant and Equipment | $-72.40M | $-150.20M | $-127.20M | $-162.70M | $-156.40M |
| Acquisitions Net | $-297.30M | $-5.00M | $-158.60M | $-1.16B | $19.90M |
| Purchases of Investments | $-267.70M | $-10.00M | $- | $- | $-2.40M |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-143.60M | $13.10M | $79.50M | $-2.20M | $-2.70M |
| Net Cash Used for Investing Activities | $-781.00M | $-152.10M | $-206.30M | $-1.33B | $-141.60M |
| Debt Repayment | $-291.30M | $-19.00M | $-212.30M | $-113.40M | $-31.50M |
| Common Stock Issued | $37.80M | $43.00M | $- | $51.30M | $- |
| Common Stock Repurchased | $-835.10M | $-474.80M | $-542.10M | $-409.80M | $-653.60M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-20.00M | $10.60M | $-1.60M | $-6.60M | $25.20M |
| Net Cash Used Provided by Financing Activities | $-1.11B | $-483.20M | $-756.00M | $-529.80M | $-659.90M |
| Effect of Forex Changes on Cash | $8.90M | $300.00K | $5.80M | $-1.70M | $4.10M |
| Net Change in Cash | $-595.50M | $416.20M | $1.17B | $469.30M | $99.20M |
| Cash at End of Period | $2.16B | $2.76B | $2.34B | $1.17B | $701.00M |
| Cash at Beginning of Period | $2.76B | $2.34B | $1.17B | $701.00M | $601.80M |
| Operating Cash Flow | $1.29B | $1.05B | $2.13B | $2.33B | $896.60M |
| Capital Expenditure | $-140.20M | $-150.20M | $-127.20M | $-162.70M | $-156.40M |
| Free Cash Flow | $1.15B | $901.00M | $2.00B | $2.17B | $740.20M |
Cash Flow Charts
| Breakdown | December 28, 2024 | September 28, 2024 | June 29, 2024 | March 30, 2024 | December 30, 2023 | September 30, 2023 | July 01, 2023 | April 01, 2023 | December 31, 2022 | September 24, 2022 | June 25, 2022 | March 26, 2022 | December 25, 2021 | September 25, 2021 | June 26, 2021 | March 27, 2021 | December 26, 2020 | September 26, 2020 | June 27, 2020 | March 28, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $201.00M | $178.60M | $194.50M | $169.90M | $246.50M | $90.60M | $-40.50M | $218.50M | $187.40M | $118.70M | $228.40M | $455.70M | $499.20M | $328.80M | $268.10M | $619.40M | $653.40M | $493.60M | $136.20M | $94.90M |
| Depreciation and Amortization | $74.00M | $74.50M | $72.30M | $73.70M | $88.40M | $75.50M | $81.20M | $80.80M | $85.90M | $106.60M | $109.40M | $106.10M | $108.00M | $117.80M | $101.10M | $95.20M | $92.80M | $94.30M | $93.60M | $93.70M |
| Deferred Income Tax | $-19.50M | $-19.80M | $-5.50M | $-29.20M | $-17.60M | $-8.90M | $-38.60M | $-35.40M | $-26.20M | $-106.00M | $-18.70M | $-19.60M | $-21.90M | $-25.80M | $-20.80M | $-11.50M | $-12.00M | $-31.10M | $-19.10M | $283.70M |
| Stock Based Compensation | $30.10M | $- | $14.60M | $25.80M | $28.70M | $19.00M | $16.90M | $23.20M | $20.50M | $14.90M | $15.30M | $17.80M | $18.70M | $14.00M | $15.40M | $17.00M | $18.60M | $29.60M | $19.90M | $15.70M |
| Change in Working Capital | $-77.20M | $106.90M | $106.80M | $28.20M | $-157.80M | $35.00M | $89.00M | $-68.90M | $-43.30M | $2.20M | $9.00M | $489.20M | $-46.20M | $26.10M | $298.10M | $-157.30M | $-153.90M | $-148.10M | $-16.40M | $-384.60M |
| Accounts Receivables | $-41.70M | $43.50M | $17.60M | $18.10M | $-38.20M | $49.50M | $30.80M | $-36.80M | $-45.00M | $78.40M | $92.30M | $149.70M | $-48.10M | $-600.00K | $282.90M | $4.10M | $-175.50M | $-296.60M | $-130.20M | $-17.90M |
| Inventory | $-36.10M | $-300.00K | $-16.70M | $-17.40M | $-13.00M | $43.60M | $7.60M | $-9.10M | $-47.00M | $-49.80M | $-60.40M | $-9.00M | $-17.40M | $-1.70M | $-36.40M | $-24.80M | $-21.20M | $22.70M | $-14.70M | $-18.40M |
| Accounts Payables | $36.20M | $-4.30M | $-200.00K | $19.50M | $7.20M | $-2.70M | $-7.10M | $-14.70M | $1.50M | $-16.90M | $-6.60M | $22.90M | $-13.80M | $11.00M | $-23.40M | $28.20M | $4.60M | $50.20M | $-7.20M | $7.50M |
| Other Working Capital | $-35.60M | $68.00M | $106.10M | $8.00M | $-113.80M | $-55.40M | $57.70M | $-8.30M | $47.20M | $-9.50M | $-9.30M | $325.60M | $33.10M | $17.40M | $75.00M | $-164.80M | $38.20M | $75.60M | $135.70M | $-355.80M |
| Other Non Cash Items | $-19.10M | $26.80M | $181.60M | $177.00M | $31.80M | $47.50M | $224.80M | $-11.90M | $29.10M | $248.60M | $-21.90M | $13.00M | $6.40M | $4.50M | $900.00K | $-10.60M | $51.10M | $3.70M | $8.80M | $14.30M |
| Net Cash Provided by Operating Activities | $189.30M | $367.00M | $405.80M | $292.40M | $220.00M | $258.70M | $332.80M | $206.30M | $253.40M | $168.60M | $330.70M | $1.06B | $564.20M | $465.40M | $662.80M | $552.20M | $650.00M | $442.00M | $223.00M | $117.70M |
| Investments in Property Plant and Equipment | $-16.80M | $-30.30M | $-43.90M | $-28.00M | $-38.00M | $-52.50M | $-36.50M | $-32.10M | $-29.10M | $-31.60M | $-25.70M | $-53.70M | $-16.20M | $-41.60M | $-35.10M | $-41.20M | $-44.80M | $-58.30M | $-35.00M | $-31.60M |
| Acquisitions Net | $-300.00K | $-297.30M | $-42.50M | $- | $-31.30M | $6.80M | $-11.80M | $20.50M | $- | $- | $-200.00K | $-1.10M | $-157.30M | $-1.40M | $-723.30M | $-435.10M | $-4.90M | $-79.60M | $- | $111.30M |
| Purchases of Investments | $- | $-267.70M | $-3.00M | $-5.00M | $-34.50M | $- | $- | $-10.00M | $-10.00M | $- | $- | $- | $- | $1.60M | $- | $-1.60M | $- | $2.40M | $- | $- |
| Sales Maturities of Investments | $32.00M | $- | $- | $- | $-22.70M | $- | $- | $-10.50M | $- | $- | $- | $- | $- | $25.80M | $- | $-25.80M | $- | $- | $- | $- |
| Other Investing Activities | $-36.90M | $-400.00K | $4.30M | $-5.50M | $22.30M | $-10.30M | $9.60M | $15.70M | $-1.90M | $-500.00K | $16.10M | $63.90M | $800.00K | $71.10M | $-19.50M | $-26.10M | $-32.60M | $53.20M | $-24.90M | $-19.60M |
| Net Cash Used for Investing Activities | $-22.00M | $-595.70M | $-42.60M | $-38.50M | $-104.20M | $-56.00M | $-38.70M | $-16.40M | $-41.00M | $-32.10M | $-9.80M | $9.10M | $-173.50M | $-43.10M | $-758.40M | $-478.20M | $-49.90M | $-137.90M | $-36.30M | $78.30M |
| Debt Repayment | $-10.20M | $-10.30M | $-10.30M | $-10.40M | $-260.30M | $-4.40M | $-4.80M | $-5.00M | $-4.80M | $-1.00M | $-249.70M | $-1.10M | $39.50M | $-104.80M | $300.60M | $-19.10M | $-303.80M | $-259.90M | $-9.70M | $481.90M |
| Common Stock Issued | $- | $12.60M | $- | $8.90M | $9.50M | $- | $- | $- | $15.10M | $- | $9.60M | $- | $6.40M | $- | $- | $- | $23.30M | $- | $- | $- |
| Common Stock Repurchased | $-517.30M | $-58.30M | $-100.00M | $-100.00K | $-676.80M | $-211.20M | $-113.60M | $-50.00M | $-100.00M | $-175.10M | $-100.00K | $-200.00M | $-167.00M | $-100.00K | $-188.30M | $-120.10M | $-101.30M | $-100.20M | $100.00K | $-267.60M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-950.00M | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-9.50M | $-800.00K | $6.50M | $6.20M | $-6.70M | $5.00M | $8.80M | $5.50M | $-8.70M | $6.30M | $9.50M | $-1.40M | $-16.00M | $972.90M | $-2.70M | $10.00M | $-23.10M | $9.20M | $-232.10M | $8.30M |
| Net Cash Used Provided by Financing Activities | $-537.00M | $-56.80M | $-103.80M | $-4.20M | $-943.80M | $-210.60M | $-109.60M | $-49.50M | $-113.50M | $-169.80M | $-240.20M | $-202.50M | $-143.50M | $-82.00M | $109.60M | $-129.20M | $-428.20M | $-350.90M | $-241.70M | $222.60M |
| Effect of Forex Changes on Cash | $-8.40M | $6.60M | $-300.00K | $-1.80M | $4.40M | $-1.40M | $-1.70M | $500.00K | $2.90M | $-2.50M | $3.80M | $1.20M | $3.30M | $2.40M | $-2.80M | $2.90M | $-4.20M | $3.60M | $-600.00K | $-300.00K |
| Net Change in Cash | $-378.10M | $-278.90M | $259.10M | $247.90M | $-823.60M | $-9.30M | $182.80M | $140.90M | $101.80M | $-35.80M | $84.50M | $870.00M | $250.50M | $342.70M | $11.20M | $-52.30M | $167.70M | $-43.20M | $-55.60M | $418.30M |
| Cash at End of Period | $1.78B | $2.16B | $2.44B | $2.18B | $1.93B | $2.76B | $2.77B | $2.58B | $2.44B | $2.34B | $2.38B | $2.29B | $1.42B | $1.17B | $827.60M | $816.40M | $868.70M | $701.00M | $744.20M | $799.80M |
| Cash at Beginning of Period | $2.16B | $2.44B | $2.18B | $1.93B | $2.76B | $2.77B | $2.58B | $2.44B | $2.34B | $2.38B | $2.29B | $1.42B | $1.17B | $827.60M | $816.40M | $868.70M | $701.00M | $744.20M | $799.80M | $381.50M |
| Operating Cash Flow | $189.30M | $367.00M | $405.80M | $292.40M | $220.00M | $258.70M | $332.80M | $206.30M | $253.40M | $168.60M | $330.70M | $1.06B | $564.20M | $465.40M | $662.80M | $552.20M | $650.00M | $442.00M | $223.00M | $117.70M |
| Capital Expenditure | $-16.80M | $-30.30M | $-43.90M | $-28.00M | $-38.00M | $-52.50M | $-36.50M | $-32.10M | $-29.10M | $-31.60M | $-25.70M | $-53.70M | $-16.20M | $-41.60M | $-35.10M | $-41.20M | $-44.80M | $-58.30M | $-35.00M | $-31.60M |
| Free Cash Flow | $172.50M | $336.70M | $361.90M | $264.40M | $182.00M | $206.20M | $296.30M | $174.20M | $224.30M | $137.00M | $305.00M | $1.01B | $548.00M | $423.80M | $627.70M | $511.00M | $605.20M | $383.70M | $188.00M | $86.10M |
Hologic Dividends
Explore Hologic's dividend history, including dividend yield, payout ratio, and historical payments.
Hologic News
Read the latest news about Hologic, including recent articles, headlines, and updates.
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript
Hologic, Inc. (NASDAQ:HOLX ) Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Mike Watts - Corporate Vice President, IR Steve MacMillan - Chairman, President and CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Anthony Petrone - Mizuho Group Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Tycho Peterson - Jefferies Casey Woodring - JP Morgan Tejas Savant - Morgan Stanley Ryan Zimmerman - BTIG Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Andrew Cooper - Raymond James Operator Good afternoon. And welcome to the Hologic's First Quarter Fiscal 2025 Earnings Conference Call.
Compared to Estimates, Hologic (HOLX) Q1 Earnings: A Look at Key Metrics
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Countdown to Hologic (HOLX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for HOLX.